These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23430136)

  • 1. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
    Koutsounas I; Giaginis C; Patsouris E; Theocharis S
    World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
    Koutsounas I; Giaginis C; Theocharis S
    World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
    Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
    Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
    Cui Y; Cai J; Wang W; Wang S
    Front Immunol; 2021; 12():690207. PubMed ID: 34149732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
    Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
    Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
    Ouaïssi M; Giger U; Sielezneff I; Pirrò N; Sastre B; Ouaissi A
    J Biomed Biotechnol; 2011; 2011():315939. PubMed ID: 20981265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
    Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
    J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
    Xiang XS; Li PC; Wang WQ; Liu L
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
    Feng W; Zhang B; Cai D; Zou X
    Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
    Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
    Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
    Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
    Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer.
    Ganai SA; Rashid R; Abdullah E; Altaf M
    Anticancer Agents Med Chem; 2017; 17(3):365-373. PubMed ID: 27281367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
    Mastoraki A; Schizas D; Vlachou P; Melissaridou NM; Charalampakis N; Fioretzaki R; Kole C; Savvidou O; Vassiliu P; Pikoulis E
    Mol Diagn Ther; 2020 Oct; 24(5):557-569. PubMed ID: 32696211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: insights into mechanisms of lethality.
    Rosato RR; Grant S
    Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.